Cabometyx

Adrenal Medulla, refractory to radioactive iodine treatment, Liver Cancer + 7 more
Treatment
2 FDA approvals
20 Active Studies for Cabometyx

What is Cabometyx

CabozantinibThe Generic name of this drug
Treatment SummaryCabozantinib is a medication used to treat several types of cancer. It was first approved in 2012 and is a type of drug known as a tyrosine kinase inhibitor. The drug is available as the brand name Cometriq and is used to treat metastatic medullary thyroid cancer. In 2016, a capsule formulation called Cabometyx was approved to treat advanced renal cell carcinoma and in 2019 it was approved for the treatment of hepatocellular carcinoma in previously treated patients.
Cometriqis the brand name
image of different drug pills on a surface
Cabometyx Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Cometriq
Cabozantinib
2012
10

Approved as Treatment by the FDA

Cabozantinib, also known as Cometriq, is approved by the FDA for 2 uses which include Advanced Renal Cell Carcinoma (aRCC) and Kidney Neoplasms .
Advanced Renal Cell Carcinoma (aRCC)
Used to treat Advanced Renal Cell Carcinoma (aRCC) in combination with Nivolumab
Kidney Neoplasms
Used to treat Advanced Renal Cell Carcinoma (aRCC) in combination with Nivolumab

Effectiveness

How Cabometyx Affects PatientsCabozantinib works by blocking proteins that help cancer cells grow and spread to other parts of the body. It can also stop the growth of new blood vessels that supply tumors with oxygen and nutrients.
How Cabometyx works in the bodyCabozantinib works by blocking specific proteins that help with cell growth and movement. These proteins are called receptor tyrosine kinases and include VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2.

When to interrupt dosage

The recommended dosage of Cabometyx is based on the diagnosed condition, including Adrenal Medulla, refractory to radioactive iodine treatment and sorafenib. The quantity of dosage fluctuates depending on the method of administration outlined in the table below.
Condition
Dosage
Administration
Adrenal Medulla
20.0 mg, , 60.0 mg, 40.0 mg, 80.0 mg
, Oral, Capsule, Capsule - Oral, Kit, Tablet, Tablet - Oral, Kit - Oral, Tablet, film coated - Oral, Tablet, film coated
refractory to radioactive iodine treatment
20.0 mg, , 60.0 mg, 40.0 mg, 80.0 mg
, Oral, Capsule, Capsule - Oral, Kit, Tablet, Tablet - Oral, Kit - Oral, Tablet, film coated - Oral, Tablet, film coated
Liver Cancer
20.0 mg, , 60.0 mg, 40.0 mg, 80.0 mg
, Oral, Capsule, Capsule - Oral, Kit, Tablet, Tablet - Oral, Kit - Oral, Tablet, film coated - Oral, Tablet, film coated
Malignant Neoplasms
20.0 mg, , 60.0 mg, 40.0 mg, 80.0 mg
, Oral, Capsule, Capsule - Oral, Kit, Tablet, Tablet - Oral, Kit - Oral, Tablet, film coated - Oral, Tablet, film coated
Treatment Naive
20.0 mg, , 60.0 mg, 40.0 mg, 80.0 mg
, Oral, Capsule, Capsule - Oral, Kit, Tablet, Tablet - Oral, Kit - Oral, Tablet, film coated - Oral, Tablet, film coated
sorafenib
20.0 mg, , 60.0 mg, 40.0 mg, 80.0 mg
, Oral, Capsule, Capsule - Oral, Kit, Tablet, Tablet - Oral, Kit - Oral, Tablet, film coated - Oral, Tablet, film coated
High Risk Patients
20.0 mg, , 60.0 mg, 40.0 mg, 80.0 mg
, Oral, Capsule, Capsule - Oral, Kit, Tablet, Tablet - Oral, Kit - Oral, Tablet, film coated - Oral, Tablet, film coated
previously treated with anti-VEGF
20.0 mg, , 60.0 mg, 40.0 mg, 80.0 mg
, Oral, Capsule, Capsule - Oral, Kit, Tablet, Tablet - Oral, Kit - Oral, Tablet, film coated - Oral, Tablet, film coated
poor or intermediate risk
20.0 mg, , 60.0 mg, 40.0 mg, 80.0 mg
, Oral, Capsule, Capsule - Oral, Kit, Tablet, Tablet - Oral, Kit - Oral, Tablet, film coated - Oral, Tablet, film coated
Kidney Neoplasms
20.0 mg, , 60.0 mg, 40.0 mg, 80.0 mg
, Oral, Capsule, Capsule - Oral, Kit, Tablet, Tablet - Oral, Kit - Oral, Tablet, film coated - Oral, Tablet, film coated

Warnings

Cabometyx Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Cabozantinib may interact with Pulse Frequency
There are 20 known major drug interactions with Cabometyx.
Common Cabometyx Drug Interactions
Drug Name
Risk Level
Description
Brigatinib
Major
The metabolism of Brigatinib can be decreased when combined with Cabozantinib.
Cabazitaxel
Major
The metabolism of Cabazitaxel can be decreased when combined with Cabozantinib.
Enasidenib
Major
The metabolism of Enasidenib can be decreased when combined with Cabozantinib.
Erlotinib
Major
The metabolism of Erlotinib can be decreased when combined with Cabozantinib.
Fluorouracil
Major
The metabolism of Fluorouracil can be decreased when combined with Cabozantinib.
Cabometyx Toxicity & Overdose RiskCabozantinib can cause serious and potentially deadly complications such as abdominal fistulas, perforations, coughing up blood, and internal bleeding from the gastrointestinal tract.
image of a doctor in a lab doing drug, clinical research

Cabometyx Novel Uses: Which Conditions Have a Clinical Trial Featuring Cabometyx?

151 active clinical trials are currently assessing the potential of Cabometyx to treat individuals who have already received anti-VEGF or sorafenib therapy, as well as High Risk Patients.
Condition
Clinical Trials
Trial Phases
previously treated with anti-VEGF
0 Actively Recruiting
Malignant Neoplasms
0 Actively Recruiting
Treatment Naive
0 Actively Recruiting
High Risk Patients
0 Actively Recruiting
sorafenib
0 Actively Recruiting
refractory to radioactive iodine treatment
0 Actively Recruiting
Liver Cancer
12 Actively Recruiting
Phase 2, Phase 4, Early Phase 1, Phase 1, Not Applicable
Kidney Neoplasms
16 Actively Recruiting
Phase 3, Not Applicable, Phase 2, Phase 1
poor or intermediate risk
0 Actively Recruiting
Adrenal Medulla
0 Actively Recruiting

Cabometyx Reviews: What are patients saying about Cabometyx?

5Patient Review
10/2/2017
Cabometyx for Cancer Involving the Kidney Cells
I got red spots on my arms and a little bit of diarrhea and vomiting. This medication also caused me to lose weight, which was an unexpected but welcomed side effect.
4.7Patient Review
1/9/2019
Cabometyx for Cancer Involving the Kidney Cells
I've only been taking this treatment for two months and it's already working better than the four months I spent on opdivo. My tumors have shrunk, though there are some nasty side effects that come with it, like intense pain and blisters on my feet.
4.3Patient Review
9/7/2019
Cabometyx for Cancer Involving the Kidney Cells
I've only been taking this medication for 35 days and I've already seen a decrease in the size of my spots. In fact, one spot in my lungs went from 1.3 cm to 0.8 cm! The only downside is the fatigue I experience; though, it's worth noting that I have a full-time job with a lot of stress.
4.3Patient Review
12/31/2020
Cabometyx for Cancer Involving the Kidney Cells
So far, Cabometyx is looking promising.
4Patient Review
8/1/2017
Cabometyx for Cancer Involving the Kidney Cells
I had some pretty severe sores on my feet and fingers, but this treatment helped to clear them up quickly.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about cabometyx

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long do you take Cabometyx for?

"Cabometyx is usually taken intravenously every 2 or 4 weeks, with nivolumab treatment lasting up to 2 years if it is decided that it is safe and effective for the patient by both the patient and doctor."

Answered by AI

What is Cabometyx used for?

"Cabozantinib is a medication used to treat advanced renal cell carcinoma."

Answered by AI

What is the success rate of Cabometyx?

"of participants receiving cabozantinib had their tumors shrink during treatment, compared with of those receiving sunitinib. people receiving cabozantinib (5%) had their tumors disappear entirely during treatment, known as a complete response."

Answered by AI

Is Cabometyx chemotherapy or immunotherapy?

"Cabometyx is a chemotherapy drug used to treat patients with advanced renal cell carcinoma and hepatocellular carcinoma. Cabometyx is used as a first-line treatment in combination with Opdivo for patients with advanced renal cell carcinoma. Cabometyx is also used for patients with hepatocellular carcinoma who have previously been treated with Nexavar."

Answered by AI

Clinical Trials for Cabometyx

Have you considered Cabometyx clinical trials? We made a collection of clinical trials featuring Cabometyx, we think they might fit your search criteria.
Have you considered Cabometyx clinical trials? We made a collection of clinical trials featuring Cabometyx, we think they might fit your search criteria.
Have you considered Cabometyx clinical trials? We made a collection of clinical trials featuring Cabometyx, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top